Protein Microarray

Creative Proteomics is a leading global company who can provide the best solution for worldwide customers in the field of protein microarray. We have successfully accomplished many projects. We guarantee the finest results for our customers all over the world.

Proteomics research is one of the major directions of life science development. Abnormal protein expression, post-translational modification or interaction with other biological molecules will lead to many diseases. Therefore, direct study of proteins can truly reveal various life phenomena. Protein microarray is a bio-detection technology developed after gene microarray. It is an important tool in protein research. It has the advantages of parallelism, rapidity and automation. The errors of parallel data detected are smaller and the accuracy is higher. The emergence of protein microarray has played a significant role in promoting the progress of biology, clinical laboratory medicine, genetics, oncology and many other disciplines.

The principle of protein microarray is to carry out special chemical treatment on solid-phase carriers, and then fix known protein molecular products on them (such as enzymes, antigens, antibodies, receptors, ligands, cytokines, etc.). According to the characteristics of these biological molecules, we can capture the specific binding proteins to be tested. Proteins (existing in plasma, serum, lymph, urine, interstitial fluid, exudate, cell lysate, secretion, etc.) are washed, purified, confirmed and biochemically analyzed. They are used to provide technical support for obtaining important life information.

Protein microarrays have irreplaceable characteristics in biology research:

• Protein level detection is irreplaceable compared with DNA/RNA microarrays that can achieve high-throughput detection of different targets.
• Traditional proteomic methods, such as two-dimensional electrophoresis, are difficult to detect the variation of low-abundance proteins.
• For multi-molecule research, conventional methods such as ELISA and western blot are time-consuming. More importantly, it is difficult to obtain enough samples for testing. A very limited sample size may not allow such multi-project testing.
• When explaining the molecular mechanisms underlying the physiological or pathological state of a cell or individual, it reveals the network of changes in signaling molecules, cytokines, receptors, regulatory factors and other biological effectors. Protein chip can accurately detect parallel changes of multiple indicators at the same time, but the combination of ELISA or other detection methods can not achieve real parallel testing.
• Protein microarray not only has good potential for precision medical treatment, but also has broad application prospects in proteomics and immunology.

Protein microarray has been successfully used in high throughput kinase detection to characterize drug specificity. At the same time, protein microarrays are often used in autoantibody profiling to identify autoimmune diseases and some cancers1. In addition, protein microarrays can be used to detect immune responses to a large number of antigens in allergic screening, identify or validate cancer biomarkers, and map epitopes during antibody development. Nowadays, the demand for protein microarray is increasing, not only in the field of scientific research, but also in the field of nursing and clinical. Among them, allergy screening and vaccine development are two areas of rapid growth. These two applications play different advantages of protein microarrays. Allergy screening saves costs by multiplex detection of homologous antibodies, while vaccine development uses very high-density chips. The main applications of protein chips are:

• Antibody therapy: discovery of therapeutic antibodies; search for candidate drugs with high value; discovery of high affinity and specific antibodies.
• Antigen autoantibodies: detection of autoantibody biomarkers; adverse drug reactions caused by autoantibodies; monitoring of immune responses in infections.
• Interaction between proteins: discovering new protein connections; predicting new protein interaction models; protein pathway maps.
• Protein interaction with small molecule: kinase inhibitor microarray; recognition of non-targeting effect; determination of the mechanism of action.
• Protein-DNA Interaction: quantitative analysis of DNA-protein Binding efficiency; study of DNA repair mechanisms; antiviral research.
• Antibody specificity: to determine the linear and conformational epitopes of the interaction; to analyze the non-targeting cross-reactions.

We offer protein microarrays that can be used to detect protein expression level (including cytokines), protein phosphorylation level, and protein interaction, which is a high throughput and applied protein level research tool. The microarray contains about 20,000 human proteins and can be used to identify post-translational modifications (PTM) of complex mixtures such as cell extracts or serum..

Sample requirements for protein microarray detection:

• Cell lysates, tissue extracts, serum and plasma samples each can be used for protein microarray detection and analysis; formalin treatment and paraffin embedding samples can also be used.
• Protein concentration requirements: 2-10 g/L, before the experiment, we will do a preliminary experiment; then suggest do formal experiments or not according to the preliminary results.

Creative Proteomics can provide commercial, custom and semi-custom protein microarray products to help researchers conduct protein function studies and protein-interacting molecule discovery. With a large and well-equipped scientist team, we are dedicated to collaborating with our clients around the world to meet your specific requirements. We have comprehensive capacity and capabilities to provide a broad and integrated portfolio of laboratory and manufacturing services. If you are interested in our services, please contact us for more details.

Reference

1. Katchman BA, et al. (2015). "Abstract 1318: A protein microarray signature of autoantibody biomarkers for the detection of HER2+ breast cancers." Cancer Research, 75(15 Supplement),1318-1318.